Physician profile
Kim M Davies
NPI 1326188046
$2,810.04
in general payments reported to CMS, 2019-2025
20 companies · $26.20 in 2025
The $26.20 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $604 · 2021: $529 · 2022: $372 · 2024: $150 · 2025: $26.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.08 | 2019-2025 | Ozempic, Rybelsus |
| Eisai INC. | $337.95 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $315.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $246.41 | 2020-2022 | |
| Amgen INC. | $209.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.94 | 2019 | |
| Lilly USA, LLC | $163.58 | 2020-2022 | |
| Allergan, INC. | $147.55 | 2020 | |
| Amarin Pharma, INC. | $136.60 | 2019 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Mdd US Operations, LLC | $124.67 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.84 | 2024 | Caplyta |
| Antares Pharma, INC. | $102.91 | 2021 | |
| Collegium Pharmaceutical, INC. | $46.84 | 2020-2024 | Xtampza |
| Novartis Pharmaceuticals Corporation | $40.13 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.79 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $16.35 | 2021 | |
| Sentynl Therapeutics, INC. | $15.31 | 2019 | |
| Indivior INC. | $15.11 | 2020 | |
| Bausch Health US, LLC | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Davies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.